Speaking at Advances in Drug Discovery and Development 2023, Dr. Brian D. Lamon, Senior VP, Chief Business Officer and Head of Biopharma Business Development at Caris Life Sciences, presented his talk on the pressing need for more novel oncology targets.

In his talk, Brian discussed the recent trends in oncology drug development, highlighting a shift towards prioritizing derisked targets over novel ones. He emphasized the importance of investing in next-generation target discovery methodologies to foster innovation. Brian introduced Caris Discovery, offering an approach to identify and validate new oncology targets through wet lab molecular interrogation and in silico analyses of clinico-genomics data. This integrated approach provides access to otherwise inaccessible targets, addressing significant areas of unmet need in cancer therapy.

свернуть